|Articles|April 15, 2002

Comfort level of ocular allergy agent is key to patient compliance

San Antonio, TX-A treatment for seasonal allergic conjunctivitis, pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., Napa, CA), was shown to be more comfortable for patients and equally effective when used twice a day during ragweed season when compared with nedocromil sodium 2% ophthalmic solution (Alocril, Allergan, Irvine, CA). These two drugs are the two latest mast-cell stabilizers that have become commercially available to treat ocular allergies.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!

Latest CME

In-Person + Virtual Event

Coordinated Care in Neovascular Retinal Disease: The Optometrist’s Role in Applying Advances in Management

February 1, 2026

In-Person Event

EnVision Summit

February 13-16, 2026

Multimedia

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

Rahul Tonk, MD, MBA

Comfort level of ocular allergy agent is key to patient compliance

Newsletter

Related Content

International Glaucoma Symposium highlights the meeting point of practice and technology

MRI study links glymphatic system dysfunction to idiopathic intracranial hypertension

FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials

FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain

FDA approves NDA labeling supplement allowing re-administration of iDose TR

Latest CME

Coordinated Care in Neovascular Retinal Disease: The Optometrist’s Role in Applying Advances in Management

EnVision Summit

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

Practical Approaches to Modern Dry Eye Treatment and Management

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials

MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies

Study finds artificial tear viscosity and shear-thinning behavior vary by formulation

Eye exams could enable earlier detection of systemic disease

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis